Outcomes of Endoscopic Submucosal Dissection in Duodenal Neuroendocrine Tumors

J Gastrointest Surg. 2022 Jan;26(1):275-277. doi: 10.1007/s11605-021-05133-8. Epub 2021 Sep 10.

Abstract

Background and aim: Endoscopic resection is recommended for small duodenal neuroendocrine tumors DNETs. However, there is limited data on the outcomes of endoscopic submucosal dissection (ESD) in DNETs. In this study, we aimed to evaluate the outcomes of ESD in DNETs.

Methods: Data of consecutive patients who underwent ESD for DNETs from January 2018 to December 2019 were analyzed, retrospectively. All the cases of ESD were performed with or without traction using rubber band and two endoclips. En-bloc resection, complete endoscopic resection (C-ER), complete pathological resection (C-PR), adverse events, and recurrence were evaluated.

Results: Twenty patients (19 males, 57.50 ± 9.32 years) underwent ESD for DNETs. DNETs measured ≤ 10 mm (7), 10-15 mm (12), and > 15 mm (1). ESD was performed with and without traction in 10 cases each. Mean operating time was 61 ± 17.38 min. En-bloc resection, C-ER, and C-PR were recorded in 90%, 95%, and 75%, respectively. Vertical margins were positive in five patients. Adverse events included perforations in 4 (20%) cases and major bleeding in one case. There was no recurrence at a mean follow-up of 17.20 ± 7.37 months.

Conclusion: ESD is feasible and effective for the management of DNETs. However, caution is advised due to a high risk of adverse events and pathologically incomplete resection.

Keywords: Duodenal; Endoscopic submucosal dissection; Neuroendocrine tumors.

MeSH terms

  • Child
  • Dissection
  • Endoscopic Mucosal Resection* / adverse effects
  • Humans
  • Intestinal Mucosa
  • Male
  • Neuroendocrine Tumors* / surgery
  • Retrospective Studies
  • Treatment Outcome